Pharmaceuticals
Innovent's MSCI ESG Rating Upgraded to A
ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-11-30 21:37
9178
Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement
Collaboration focused on novel target discovery in prostate cancer LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology ...
2023-11-30 20:00
2251
Triple Negative Breast Cancer: Expert Consensus on Local Treatment Options
Hong Kong Breast Cancer Foundation Launches "Immunotherapy Drug Financial Assistance Programme" to Benefit Patients in Need HONG KONG, Nov. 30, 2023 /PRNewswire/ -- Breast cancer is the leading cancer facing women inHong Kong. According to the statistics released by the Hong Kong Cancer Registry...
2023-11-30 15:00
2585
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
SHANGHAI, Nov. 30, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that its New Drug Application (NDA) for Nefecon®...
2023-11-30 07:25
5492
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candid...
2023-11-30 04:15
2729
Unither Pharmaceuticals celebrates 30 years of innovation and expertise
PARIS, Nov. 30, 2023 /PRNewswire/ -- Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 30 years in business. In 1993, Unither Pharmaceuticals began operations by acquiring a 17-man pharmaceutical plant that produced 3 pharmaceutical forms. T...
2023-11-30 02:42
3688
VISTA Eye Specialist Unveils Innovative Solution for Reading Problems
PETALING JAYA, Malaysia, Nov. 29, 2023 /PRNewswire/ -- VISTA Eye Specialist (VISTA) proudly introduces the groundbreaking EVO Viva Implantable Collamer Lens (Viva) to address the dual challenge of short-sightedness and reading problems (presbyopia) among patients aged above 40. This cutting-edge ...
2023-11-29 08:00
2906
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
GAITHERSBURG, Md., Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Or...
2023-11-28 19:00
4305
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)
YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
2023-11-28 09:48
3227
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce that its Osong factory in Korea achieved Good Manufacturing Practice (GMP) certification from the Regulatory Authority ofBrazil, ANVISA. Daewoong Pharmaceutical, represented by CEO Seng-ho Jeon and ...
2023-11-28 08:00
2889
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia
- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK - DxVx plans to proceed its own clinical trials in Asia, including Korea and China SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vacc...
2023-11-24 22:00
5678
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of early iron deficiency diagnosis and treatment and its impact on quality of life ST. GALLEN, SWITZERL...
2023-11-24 15:00
5143
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the ...
2023-11-24 12:54
6761
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-24 08:42
5485
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL...
2023-11-23 16:04
6086
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-23 08:00
4861
Ark Biopharmaceutical Receives IND Approval from NMPA for AK0610, a Respiratory Syncytial Virus Neutralizing Antibody
SHANGHAI, Nov. 23, 2023 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announces that it had received IND approval from National Medical Products Administration (NMPA) for a novel antibody drug AK0610. This antibody drug is bioengineered based on a neutralizing antibody origina...
2023-11-23 08:00
4163
CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan
First Reimbursed Amyloid PET Diagnostic Tool in Japan TOKYO and BERLIN, Nov. 23, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben18F injection) has been approved from the Ministry of Health, Labor, and ...
2023-11-23 01:00
3197
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ot...
2023-11-22 12:40
7616
XtalPi and EDDC Sign New Collaboration, Empowering Biomedical Innovation with Robotics and Large Language Models
SHENZHEN, China, Nov. 22, 2023 /PRNewswire/ -- Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC),Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboratio...
2023-11-22 09:00
4069
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
21026
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
19494
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
9545